Greene Barry E Insider Trading Activity (DYN)

Summary

Updated Jul 16, 2026

Greene Barry E has filed 2 SEC Form 4 filings across 2 companies in the last 90 days.

Profile

Barry E. Greene is a prominent executive in the biotechnology sector, currently serving as President and CEO of Sage Therapeutics, Inc. He has also held leadership roles at Karyopharm Therapeutics Inc. Greene has a strong background in the pharmaceutical industry, contributing to the development of innovative therapies.

Role	Insider
Notability	30/100

Board memberships

Sage Therapeutics, Inc.
Karyopharm Therapeutics Inc.

Awards & honors

Leadership in biotechnology
Development of innovative therapies
CEO of Sage Therapeutics

Recent Transactions

Date	Ticker	Company	Code	Shares	Price	Value
2026-05-26	KPTI	Karyopharm Therapeutics Inc.	A — Grant or award	15.5K	$0.00
2025-07-31	SAGE	Sage Therapeutics, Inc.	D — Derivative transaction	53.2K	—
2025-07-31	SAGE	Sage Therapeutics, Inc.	J — Other acquisition / disposition	46.9K	—
2025-04-10	SAGE	Sage Therapeutics, Inc.	F — Tax withholding / forfeiture	4.9K	$6.91	$34K
2025-04-10	SAGE	Sage Therapeutics, Inc.	A — Grant or award	20.0K	$0.00

Frequently Asked Questions

Who is Greene Barry E?

How many SEC Form 4 filings has Greene Barry E submitted recently?

2 primary Form 4 filings in the last 90 days, covering 2 companies.

Where can I see all of Greene Barry E's SEC filings?

All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.

Greene Barry E — SEC Form 4 Insider Trading Activity